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ABSTRACT
Bronchiolitis obliterans (BO) is a serious complication after allogeneic stem cell transplantation. We hypothe-
sized that single nucleotide polymorphisms (SNPs) of the NOD2/CARD15 gene (5 NOD2/CARD15 variants)
contribute to changes in host defense and subsequent alloreaction, leading to BO. We analyzed 427 donor–re-
cipient pairs for the association of NOD2/CARD15 variants (SNP8 [Arg702Trp], SNP12 [Gly908Arg], and
SNP13 [Leu1007fsinsC]) with BO occurrence. Overall, 11 patients (2.6%) developed BO. The cumulative inci-
dence of BO rose from 1.3% in donor–recipient pairs without mutation to 18.7% in pairs with donor or recipient
NOD2/CARD15 variants (P\ .001). Recipient NOD2/CARD15 variants alone led to BO in 22.3% (P\ .001),
whereas donor variants alone associated with BO in 13.2% (P 5 .04). Multivariate analysis proved recipient
but not donor NOD2/CARD15 variants to be a novel independent risk factor for BO development, and
NOD2/CARD15 typing may help identify patients at increased risk for BO.
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Bronchiolitis obliterans (BO) is a serious pulmo-
nary complication leading to late morbidity and
decreased survival after allogeneic stem cell
transplantation (allo-SCT). The pathophysiology of
BO has yet to be defined, but experimental data from
heterotopic trachea transplant models suggest that
both loss of bronchial epithelial cell (EC) integrity
and an alloantigen-reactive T cell response are in-
volved [1,2]. We recently reported an association ofsingle nucleotide polymorphisms (SNPs) of the nucle-
otide-binding oligomerization domain containing 2/
caspase recruitment domain family, member 15
(NOD2/CARD15) gene, resulting in a diminished nu-
clear factor-kappa B (NF-kb) response to bacterial
cell wall products, leading to increased graft-versus-
host disease (GVHD) severity and treatment-related
mortality (TRM) [3,4]. Because NOD2/CARD15 is ex-
pressed not only in monocytes/macrophages and intes-
tinal Ecs, but also in bronchial Ecs, as shown by67
68 G. C. Hildebrandt et al.Hippenstiel et al. [5] and our group (unpublished data),
we hypothesized that NOD2/CARD15 variants con-
tribute to changes in host defense and thus facilitate al-
loreaction, leading to BO.
PATIENTS AND METHODS
Patients
The study group comprised 467 patients of Cauca-
sian ethnic background who underwent allo-SCT at 4
European SCT centers (Regensburg and Rostock,
Germany; Vienna, Austria; and Barcelona, Spain). A
total of 427 donor–recipient pairs were included in
the analysis (Table 1), because no information about
donor NOD2/CARD15 mutations could be obtained
for 40 patients. Mutations assessed included SNP8
(Arg702Trp), SNP12 (Gly908Arg), and SNP13
(Leu1007fsinsC). Median time of follow-up was 674
days (range, 6-3484 days). BO development was as-
sessed by pulmonary function tests, including forced
expiratory volume in the first second (FEV1), single-
breath diffusion lung capacity for carbon monoxide
(DLCO), total lung capacity (TLC), vital capacity, re-
sidual volume (RV), and functional residual capacity
(FRC). BO was defined as an FEV1 # 80% of pre-
dicted value (n 5 11/11) plus RV%TLC . 25% or
FRC%TLC. 40%. Lung function score categorizing
incorporating changes in FEV1 and DLCO was done
as described previously [6,7]. Supportive histopatho-
logic findings of BO or pulmonary GVHD were found
in 3 patients, and computed tomography (CT) scans
demonstrating BO or BO-organizing pneumonia
were found in 7 and 2 patients, respectively.
Collection of DNA Samples, Informed Consent,
and Allelic Discrimination of the NOD2/CARD15
Gene
DNA from 467 patients and from 427 of their do-
nors was collected and retrospectively analyzed by alle-
lic discrimination of the NOD2/CARD15 gene as
described previously [3]. At admission and before
stem cell collection, all patients and donors had given
informed written consent to genetic analysis of hema-
topoeitic stem cell transplantation—related complica-
tions in their biological samples. The study was
approved by each center´s ethics committee.
In addition, the presence of NOD2/CARD15 mu-
tations was determined in an independent group of 4
patients who developed BO after allo-SCT at Hann-
over Medical University.
Statistical Analysis
Individuals heterozygous for at least 1 of the 3
NOD2/CARD15 SNPs analyzed (SNP8, SNP12,
SNP13) were considered variant, whereas individuals
lacking these SNPs were considered wild-type. Geno-
type frequencies observed in donors and recipientswere compared with Hardy-Weinberg expectations
using c2 statistics. The development of BO was ana-
lyzed in relation to NOD2/CARD15 variants by form-
ing groups according to the occurrence of any variant
in (1) recipient and donor, (2) in donors only, (3) in re-
cipients only, (4) in either recipient or donor, or (5)
none. Cox regression was used to compare groups
and analyze hazard ratios. The following variables
were included in the univariate analysis: NOD2/
CARD15 variants, acute and chronic GVHD (aGVHD,
cGVHD), recipient age, stage of disease, donor type
(sibling vs unrelated), stem cell source, T cell depletion
(TCD), conditioning regimen (standard conditioning
vs reduced-intensity conditioning [RIC]; busulfan; total
body irradiation [TBI]). Multivariate analysis by Cox
regression included NOD2/CARD15 variants, acute
and chronic GVHD, stem cell source, recipient age,
conditioning intensity, and stage of disease. For cumu-
lative BO development, actuarial curves were obtained
by the Kaplan-Meier method and compared statistically
using the log-rank test. Allele frequencies were com-
pared using thec2 test. P values were 2-sided, and a sig-
nificance level of a5 .05 was used.
RESULTS
We investigated the association of variants of the
NOD2/CARD15 gene with the development of BO
in 427 donor–recipient pairs after allo-SCT. First,
we determined the frequency of NOD2/CARD15 vari-
ants in donors and recipients by allelic discrimination
for SNP8 (Arg702Trp), SNP12 (Gly908Arg), and
SNP13 (Leu1007fsinsC), which represent 82% of
the mutated chromosomes. Genotype frequencies
both in recipients and donors were consistent with
Hardy-Weinberg equilibrium, comparing the ob-
served with the expected genotype frequencies by c2
statistics for SNP8 (donors,P5 .42; recipients,P5 .55),
SNP12 (donors, P 5 .98; recipients, P 5 .94), and
SNP13 (donors,P5 .93; recipients,P5 .93). Allele fre-
quencies for SNP8 were 4.46% for donors and 5.04%
for recipients, those for SNP12 were 0.94% for donors
and 1.64% for recipients, and those for SNP13 were
1.76% for donors and 1.91% for recipients. Total allele
frequencies for these 3 main NOD2/CARD15 muta-
tions were 7.16% for donors and 8.59% for recipients,
and both individual and total frequencies were compa-
rable to those reported by other studies [8-10].
At least 1 NOD2/CARD15 variant was carried by
15.7% of all recipients and 12.9% of all donors. In
323 pairs (75.6%), both donor and recipient carried
wild-type alleles. In 49 pairs (11.4%), the recipient
only had at least 1 mutation; in 37 pairs (8.7%), the do-
nor only had at least 1 mutation. NOD2/CARD15 var-
iants of both donor and recipient were present in 18
pairs (4.2%). Patient- and donor-specific characteris-
tics, as well as transplantation-specific procedures,
NOD2/CARD15 and Bronchiolitis Obliterans 69Table 1. Major characteristics of patients, donors, and transplantation procedures in donor-recipient pairs without and with NOD2/CARD15 variants
Recipient var(1) Donor var(1)
Recipient 1
Donor var(1) Neither var(1)
Number of patients 49 37 18 323
Patient sex
Female 19 (38.8%) 14 (37.8%) 6 (33.3%) 149 (46.3%)
Male 30 (61.2%) 23 (62.2%) 12 (66.7%) 173 (53.7%)
Patient age, years 39.0 (19-63) 39.8 (18-64) 40.6 (16-58) 40.7 (16-65)
Donor age, years 36.0 (17-57) 37.6 (21-58) 38.9 (12-53) 39.0 (11-66)
Disease entity
Acute leukemia 26 (53.1) 20 (54.1%) 11 (61%) 142 (44.0%)
Chronic leukemia 10 (20.4%) 8 (21.6%) 2 (11%) 81 (25.1%)
Lymphoma 9 (18.4%) 7 (18.9%) 4 (22%) 85 (26.3%)
BMF 2 (4.1%) 2 (5.4%) 1 (6%) 12 (3.7%)
Others 2 (4.0%) 0 (0%) 0 (0%) 3 (0.9%)
Disease stage
early/intermediate 31 (63.3%) 23 (62.2%) 7 (39%) 203 (62.8%)
advanced 18 (36.7%) 14 (37.8%) 11 (61%)* 120 (37.2%)
Donor type
Sibling 18 (36.7%) 13 (35.1%) 16 (89%) 200 (61.9%)
URD 31 (63.3%)* 24 (64.9)* 2 (11%) 122 (37.8%)
MRD 0 (0%) 0 (0%) 0 (0%) 1 (0.3%)
T cell depletion
None 31 (63.3%) 28 (75.7%) 15 (83%) 194 (60.1%)
ATG/campath/CD341selection 18 (36.7%) 9 (24.3%) 3 (17%) 129 (39.9%)
Conditioning
Standard 36 (73.5%) 31 (83.8%) 14 (78%) 237 (73.4%)
RIC 13 (26.5%) 6 (16.2%) 4 (22%) 86 (26.6%)
TBI yes 34 (81%) 23 (79.3%) 12 (70.6%) 188 (64.8%)
TBI no 8 (19%) 6 (20.7%) 5 (29.4%) 102 (35.2%)
Busulfan yes 0 (0%) 2 (7.1%) 2 (11.8%) 11 (3.9%)
Busulfan no 42 (100%) 26 (92.9%) 15 (88.2%) 270 (96.1%)
Stem cell source
Bone marrow 21 (42.9%) 16 (43.2%) 3 (17%) 97 (30.0%)
PBSC 28 (57.1%) 21 (56.8%) 15 (83%) 226 (70.0%)
Acute GVHD
\2 32 (66.7%) 23 (62.2%) 9 (50%) 209 (65.1%)
$2 16 (33.3%) 14 (37.8%) 9 (50%) 112 (34.9%)
Chronic GVHD
No 28 (57.1%) 18 (50%) 12 (71%) 199 (61.6%)
Yes 21 (42.9%) 18 (50%) 5 (29%) 124 (38.4%)
BO
Yes/no 4/45 2/35 2/16 3/320
var(1) indicates presence of at least one of the SNP8, SNP12, or SNP13; standard conditioning regimens consisted of 8 Gy to 12 Gy fractionated
total body irradiation (TBI) followed by high-dose cyclophosphamide or classic busulfan/cyclophosphamide; reduced-intensity conditioning
(RIC) consisted mainly of fludarabin/BCNU and melphalan regimens. For T cell depletion, serotherapy with antithymocyte globulin (ATG)
or with alemtuzumab (Campath) was given in the course of pretransplantation conditioning. Some patients were enrolled on protocol for
CD341selection. All criteria were equally distributed between groups expect* increased percentage of URD donors in the recipient var(1)
and donor var(1) group and more patients with advanced stage of disease at time of transplantation in the recipient var(1) and donor var(1)
group. BMF, bone marrow failure syndrome (severe aplastic anemia, osteomyelofibrosis and sclerosis, paroxysmal nocturnal hemoglobinuria).were distributed equally between patient–donor pairs
with and without mutations (Table 1).
Eleven patients (2.6%) developed BO, with a me-
dian time of diagnosis of 581 days (range, 186-1407
days) after allo-SCT (Table 2). As shown in Table 3,
NOD2/CARD15 variants were observed at higher fre-
quencies in the donor–recipient pairs with BO than in
those donor–recipient pairs that did not develop BO
(donor: 36.4% vs 12.2%, P 5 .04; recipient: 54.5%
vs 14.6%, P 5 .003; Figure 1A). These data were
confirmed by analysis of NOD2/CARD15 variants in
a second independent cohort of 4 cases with BO afterallo-SCT from the University of Hannover that found
that 75% of the donors and 50% of the recipients car-
ried a mutation (Table 4).
We next compared the pathophysiologic relevance
of donor and recipient NOD2/CARD15 variants for
BO development by determining the cumulative inci-
dence in dependence on the absence or presence of
a mutated allele in the donor, the recipient, or both.
The incidence of BO increased from 1.3% in the
wild-type group to 18.7% when the donor, the recipi-
ent, or both carried a NOD2/CARD15 variant
(P \ .001; Figure 1B). The incidence was 22.3%
70 G. C. Hildebrandt et al.(P\ .001; Figure 1C) if a mutation was present in the
recipient only, 13.2% if a mutation was present only in
the donor (P 5 .04; Figure 1D), and 13.8% if a muta-
tion was present in both the donor and recipient (P\
.001; data not shown). Cox regression univariate anal-
ysis and hazard ratio (HR) assessment revealed that re-
cipient variants (P\ .0001; HR5 9.0), donor variants
(P 5 .02; HR 5 4.3), cGVHD (P 5 .02; HR 5 11.7),
and advanced stage of disease (P5 .03; HR5 3.9) were
significant risk factors for BO development, whereas
aGVHD, recipient age, TCD, conditioning regimen
(standard vs RIC; busulfan; TBI), stem cell source,
and donor type were not.
These data suggest that NOD2/CARD15 variants
of both donor and recipient may contribute to the in-
creased risk of developing BO. However, multivariate
Cox regression analysis revealed a much stronger im-
pact of recipient NOD2/CARD15 variants than donor
Table 2. Pulmonary function results in 11 patients developing BO after
allo-SCT
FEV1* DLCO* RV%TLC FRC%TLC VC*
Re 1‡ 34 44 75 39 40
Re 20†‡ 48 40 41 76 40
Re 64 28 62 46 32 68
Re 112†‡ 75 62 45 55 90
Ro 27‡ 53 55 43 n/a 74
Ro 84†‡ 41 58 55 n/a 63
V165‡ 19 60 62 73 47
V180† 54 43 45 75 55
BA 70369542‡ 33 n/a n/a n/a n/a
BA 371997‡ 33 48 31 n/a 68











Re 1‡ 6 5 11 IV
Re 20†‡ 5 5 10 IV
Re 64 6 3 9 III
Re 112†‡ 2 3 5 II
Ro 27‡ 4 4 8 III
Ro 84†‡ 5 4 9 III
V165‡ 6 3 9 III
V180† 4 5 9 III
BA 70369542‡ 6 n/a 6 III
BA 371997‡ 6 5 11 IV
BA 336166 4 4 8 III
LFS indicates lung function score; TLC, total lung capacity; VC,
vital capacity; RV, residual volume; FRC, functional residual
capacity; n/a, not available.
*% of predicted value; **LFS5 score FEV11 score DLCO;\80%
of predicated, 1;70-79%, 2; 60-69%, 3; 50-59%, 4; 40-49%, 5;\40%,
6. *** lung function category: 1 (normal) 5 LFS 2; II (mild) 5 LFS
3-5; III (moderate) 5 LFS 6-9; IV (severe) 5 LFS 10-12.
†Histological changes consistent with BO / pulmonary GVHD.
‡CT scan consistent with BD (n57) or BO-organizing pneumonia
(n52).variants on BO development, with only cGVHD (P
5 .007; HR 5 22.9) and NOD2/CARD15 mutations
of the recipient (P5 .004; HR5 9.0) remaining as in-
dependent risk factors (Figure 1E). Interestingly, no
association was found between cGVHD and NOD2/
CARD15 variants of the recipient (P 5 .6), the donor
(P 5 .2), recipient or donor (P 5 .4), or recipient and
donor (P5 .4) in our cohort, supporting a unique con-
tribution of NOD2/CARD15 mutations to BO but not
to cGHVD in general.
DISCUSSION
BO is a late-onset noninfectious pulmonary com-
plication of allo-SCT that primarily affects the
smaller airways, leading to severe, progressive pulmo-
nary obstruction and impaired survival. BO can man-
ifest months to years after allo-SCT, with a reported
incidence between 2% and 10% [11-14]. Reported
risk factors for BO development include aGVHD
and cGVHD, busulfan-based conditioning, periph-
eral blood stem cell transplantation (PBSC), long du-
ration between diagnosis and transplantation, male
recipients receiving transplants from female donors,
and prior episode of interstitial pneumonitis
[11,12,14,15,18]. Risk factors differed among the
studies because of differences in study design, patient
characteristics and disease definitions. Santo Tomas
et al. [11] performed an analysis on the International
Bone Marrow Transplant Registry (IBMTR) data-
base, finding 76 cases of BO in 6275 patients. Consis-
tent with previous studies [15-17], these authors
found, among others, aGVHD as a risk factor for
BO, but were unable to obtain an unbiased estimate
of the effect of cGVHD because the registry ques-
tionnaire incorporated BO as a manifestation of
cGVHD [11]. In contrast, in the present study, we
classified cGVHD and BO separately, and multi-
variate analysis revealed a significant association
between cGVHD and an increased risk of BO develop-
ment, confirming previous reports [12,14,17,19-22].
aGVHD, which has been described not only as a po-
tential risk factor for BO, but also as a definite risk
factor for subsequent cGVHD, did not influence
the development of BO in our study. In addition,
no association between the development of chronic
GVHD and NOD2/CARD15 variants of donor, re-
cipient, or both was seen. This strongly suggests
that BO pathophysiology is not based on alloanti-
gen-specific immune responses of the donor immune
system against host lung tissue alone, but rather in-
volves additional distinct and unique features that
do not apply to all patients, but rather define patients
at higher risk for BO development, helping explain
why only a small percentage of patients develop this
deleterious complication after allogeneic SCT.
NOD2/CARD15 and Bronchiolitis Obliterans 71Table 3. Presence of NOD2/CARD15 variants in recipients (a), donors (b), and donors and recipients (c) of patients with BO after allo-SCT, Regensburg-
Rostock-Vioenna-Barcelona cohort
Recipient SNP
SNP 8 SNP 12 SNP 13 SNP 8 and 12 SNP 8 and 13 SNP 12 and 13
Re 1 0 0 0 0 0 0
Re 20 0 1 0 0 0 0
Re 64 1 0 0 0 0 0
Re 112 1 0 0 0 0 0
Ro 27 1 0 0 0 0 0
Ro 84 0 0 0 0 0 0
V165 0 0 0 0 0 0
V180 0 0 0 0 0 0
Ba 336166 0 0 0 0 0 0
Ba 371997 1 0 0 0 0 0
Ba 70369542 1 0 0 0 0 0
5/11 1/11 0/11 0/11 0/11 0/11
45.5% 9.1% 0% 0% 0% 0%
Donor SNP
SNP 8 SNP 12 SNP 13 SNP 8 and 12 SNP 8 and 13 SNP 12 and 13
Re 1 1 0 0 0 0 0
Re 20 0 0 0 0 0 0
Re 64 0 0 0 0 0 0
Re 112 1 0 0 0 0 0
Ro 27 0 0 0 0 0 0
Ro 84 0 0 0 0 0 0
V165 0 1 0 0 0 0
V180 0 0 0 0 0 0
Ba 336166 0 0 0 0 0 0
Ba 371997 1 0 0 0 0 0
Ba 70369542 0 0 0 0 0 0
3/11 1/11 0/11 0/11 0/11 0/11
27.3% 9.1% 0% 0% 0% 0%
Donor SNP8,






Re 1 1 0 0
Re 20 0 1 0
Re 64 0 1 0
Re 112 1 1 1
Ro 27 0 1 0
Ro 84 0 0 0
V165 1 0 0
V180 0 0 0
Ba 336166 0 0 0
Ba 371997 1 1 1
Ba 70369542 0 1 0
4/11 6/11 2/11
36.4% 54.5% 18.2%NOD2/CARD15, an intracellular receptor for the
bacterial cell wall product muramyldipeptide (MDP),
is expressed in epithelial cells of the intestinal tract,
in bronchial epithelium, and in macrophages, mono-
cytes, and antigen-presenting cells [5,23-29]. After
infection of pulmonary epithelial cells with Streptococ-
cus pneumoniae, expression of NOD2 increases in
these cells in vitro and overall expression is up-regu-lated in mouse lungs infected with pneumococci [27].
TNFa and IFNg up-regulate the expression of
NOD2/CARD15 in gastrointestinal epithelial cells
[29] as well as in bronchial epithelial cells, as has
been demonstrated by our group (manuscript in
preparation). The antimicrobial peptides a- and b-
defensins, which participate in the innate host im-
mune defense, have been described as markers of
72 G. C. Hildebrandt et al.Figure 1.NOD2/CARD15 variants (var) of the recipient independently increase the risk of developing BO after allo-SCT.
A, Frequency of NOD2/CARD15 variants in donors and recipients of patients with (n5 11) and without (n5 416) BO ()P
\ .05). B-D, Cumulative incidence of BO after allo-SCT depending on whether (B) the recipient, the donor, or both carry
a NOD2/CARD15 variant (n5104); (C) only the recipient has a NOD2/CARD15 variant (n5 49); or (D) only the donor has
a NOD2/CARD15 mutation (n 5 37). Wt represents wild-type controls, that is, neither donor nor recipient has a NOD2/
CARD15 variant (n5 323) ()P\ .05; ))P\ .01). E, Chronic GVHD and recipient NOD2/CARD15 variant are indepen-
dent risk factors for BO development.bronchial inflammation as well as of BO develop-
ment after lung transplantation [30-32], and MDP–
NOD2/CARD15 interactions lead to the activation
of the innate immune system by inducing a- and b-
defensin secretion as a first line of defense in re-
sponse to a bacterial attack and also by increasingthe production of inflammatory cytokines, such as tu-
mor necrosis factor-a, interleukin (IL)-1b, and IL-8
[23,24,28,33-39].
By demonstrating the important role for NOD2/
CARD15 in the development of BO, our study pro-
vides the first report directly linking BO with mutationTable 4. Presence of NOD2/CARD15 variants in recipients and donors with BO after allo-SCT, Hannover cohort
Recipient SNP Donor SNP
SNP 8 SNP 12 SNP 13 SNP 8, 12, or 13 SNP 8 SNP 12 SNP 13 SNP 8, 12, or 13
H10260 2 2 1 1 1 2 2 1
H10553 2 2 2 2 2 1 2 1
H10565 2 2 2 2 2 2 2 2
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bacterial cell wall products as a critical part of the
innate immune system. Decreased monocyte/
macrophage function and altered epithelial defense
mechanisms may increase susceptibility to subclinical
pulmonary infections, causing dysregulation and pro-
longation of inflammation [23-26] and possibly result-
ing in bronchial epithelial injury, obliteration of
bronchi and bronchioli, and airway obstruction. Vari-
ous models have shown a loss of airway epithelium as-
sociated with the development of BO [40-42], and the
integrity of the airway epithelium seems essential to
the prevention of BO [43]. Furthermore, Hill et al.
[44] recently demonstrated a preventive role of inter-
feron (IFN)-g on the development of idiopathic pneu-
monia syndrome after allo-SCT, mediated through
lung parenchymal cells. This leads to the speculation
that in the context of BO, increasing NOD2/CARD15
expression in epithelial cells by IFNg administration
may be beneficial in patients carrying a NOD2/
CARD15 mutation by compensating for the loss of
function implied by the mutation.
The association of BO with activation of the innate
immune system is also supported by recent reports on
successful treatment of BO using azithromycin [45],
although the exact mechanism is not yet understood.
Further supporting this theory, an association be-
tween the innate immune system and obstructive air-
way disease after allo-SCT has been recently
described, with mutations in the bactericidal/perme-
ability-increasing protein gene leading to an increased
risk of decreased airflow [46]. In addition, NOD2/
CARD15 signaling has been shown to directly cross-
talk with and potentially down-regulate T cell re-
sponses [47], thus NOD2/CARD15 variants also may
contribute to BO development by preventing protec-
tive T cell responses and augmenting cytotoxic T lym-
phocyte injury to the lung in an alloantigen- specific
manner. Whereas the NOD2/CARD15 variants ana-
lyzed in this study are located near the C-terminal leu-
cine-rich repeat domain and cause decreased NF-kB
activation, mutations affecting the central nucleotide–
binding NACHT domain result in increased NF-kB
activation and have been shown to play a role in Blau
syndrome and in early-onset sarcoidosis [48,49].
Although Blau syndrome has historically been seen
as a familial inflammatory granulomatous disease
affecting the eyes, skin, and joints, Becker et al. [49]
recently reported a case of interstitial pneumonitis in
Blau syndrome. Pulmonary involvement and manifes-
tation of these diseases strongly support the sugges-
tion that NOD2/CARD15 mutations leading to
NF-kB hyperactivation also can promote certain
lung pathologies, and emphasize the contributing
role of the innate immune system, although the un-
derlying pathophysiologic mechanisms may be com-
pletely different.In summary, our data strongly suggest that NOD2/
CARD15 mutations represent a novel risk factor for
the development of BO, and thus that future risk as-
sessment before allo-SCT using NOD2/CARD15 typ-
ing may help identify patients at greater risk for BO
and improve their clinical outcome after allo-SCT.
In addition, our data further strengthen the role of
both adaptive and innate immune responses and their
interplay in SCT immunology.
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